...
首页> 外文期刊>APL Materials >Tetrahedral framework nucleic acids as an advanced drug delivery system for oligonucleotide drugs
【24h】

Tetrahedral framework nucleic acids as an advanced drug delivery system for oligonucleotide drugs

机译:四面体骨架核酸作为寡核苷酸药物的晚期药物输送系统

获取原文
           

摘要

Nucleic acid therapy has played a promising role in the treatment of many diseases, such as cancer, infections, immune diseases, and neurodegenerative diseases. However, its application is still limited mainly because of poor cell-entry performance and low resistance to in vivo degradation. Tetrahedral framework nucleic acids (tFNAs) have shown potential in delivering low-molecular-weight drugs owing to their stability, biocompatibility, cell-entry performance, and flexible drug-loading ability. In particular, tFNAs can successfully deliver oligonucleotide drugs with improved effects and co-deliver oligonucleotide drugs with other drugs for synergistic effects. In this review, the recent progress on tFNA-based delivery of oligonucleotide drugs is outlined by single delivery systems—through sequence extension and complementation, and co-delivery systems—through multiple sequence extension, drug–DNA interactions, and specific binding. Furthermore, the current limitations and future developments of tFNA-based delivery of oligonucleotide drugs are discussed.
机译:核酸治疗在治疗许多疾病(如癌症,感染,免疫疾病和神经变性疾病)中发挥了有希望的作用。然而,它的应用仍然是有限的,主要是因为细胞入学性能差和低阻力在体内降解。由于其稳定性,生物相容性,细胞进入性能和柔性药物负载能力,四面体骨架核酸(TFNA)示出了递送低分子量药物。特别是,TFNA可以成功地递送具有改善的效果的寡核苷酸药物,并与其他药物共同递送寡核苷酸药物以进行协同作用。在该综述中,通过单递送系统 - 通过序列延伸和互补和互补,通过多序列延伸,药物DNA相互作用和特异性结合来概述最近基于TFNA的寡核苷酸药物的进展。此外,讨论了基于TFNA的寡核苷酸药物递送的当前限制和未来发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号